Ivermectin therapy is associated with changes in SARS-CoV-2 RNA load in asymptomatic patients: a randomized controlled trial

Mouawia et al., Trials, doi:10.1186/s13063-026-09736-x, ChiCTR2000033627, May 2026
Early treatmentRCT · 126 patients · Lebanon · Nov – Dec 2021
Ivermectin for COVID-19

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.0000000001 from 106 studies, recognized in 24 countries.

No treatment is 100% effective.
Protocols combine treatments.

RCT of 126 asymptomatic PCR+ patients with high viral load, showing improved recovery and significantly lower viral load with ivermectin treatment. All patients received zind and vitamin C.
The trial selected for patients with high viral load that were still asymptomatic - i.e., patients were treated early before significant progression and had received a high viral load, which may be favorable conditions for the strong viral load improvement seen.
This is the 54th COVID-19 RCT for ivermectin, which collectively show efficacy with p=0.000000027.
This is the 106th COVID-19 controlled study for ivermectin, which collectively show efficacy with p<0.0000000001.
OutcomeImprovementEffect · pTreatmentControl
risk of hospitalization 55.6% lower · RR 0.44 · p = 0.24 55.6% lowerRR 0.44p = 0.24 4 of 63 (6.3%) 9 of 63 (14.3%) treatment 4 of 63 (6.3%), control 9 of 63 (14.3%)NNT 13day 4
risk of no recovery 30.9% lower · RR 0.69 · p = 0.007** 30.9% lowerRR 0.69p = 0.007** 63 63 treatment 63, control 63all symptoms combined
risk of no recovery 81.2% lower · RR 0.19 · p = 0.002** 81.2% lowerRR 0.19p = 0.002** 3 of 63 (4.8%) 16 of 63 (25.4%) treatment 3 of 63 (4.8%), control 16 of 63 (25.4%)NNT 4.8feverday 4
risk of no recovery 33.3% higher · RR 1.33 · p = 0.52 33.3% higherRR 1.33p = 0.52 16 of 63 (25.4%) 12 of 63 (19.0%) treatment 16 of 63 (25.4%), control 12 of 63 (19.0%)coughday 4
risk of no recovery 60.0% lower · RR 0.40 · p = 0.44 60.0% lowerRR 0.40p = 0.44 2 of 63 (3.2%) 5 of 63 (7.9%) treatment 2 of 63 (3.2%), control 5 of 63 (7.9%)NNT 21sore throatday 4
risk of no recovery 26.3% lower · RR 0.74 · p = 0.42 26.3% lowerRR 0.74p = 0.42 14 of 63 (22.2%) 19 of 63 (30.2%) treatment 14 of 63 (22.2%), control 19 of 63 (30.2%)NNT 13dyspneaday 4
risk of no recovery 33.3% lower · RR 0.67 · p = 0.74 33.3% lowerRR 0.67p = 0.74 4 of 63 (6.3%) 6 of 63 (9.5%) treatment 4 of 63 (6.3%), control 6 of 63 (9.5%)NNT 32pneumoniaday 4
risk of no recovery 40.0% lower · RR 0.60 · p = 0.02* 40.0% lowerRR 0.60p = 0.02* 21 of 63 (33.3%) 35 of 63 (55.6%) treatment 21 of 63 (33.3%), control 35 of 63 (55.6%)NNT 4.5headacheday 4
risk of no recovery 46.2% higher · RR 1.46 · p = 0.31 46.2% higherRR 1.46p = 0.31 19 of 63 (30.2%) 13 of 63 (20.6%) treatment 19 of 63 (30.2%), control 13 of 63 (20.6%)anosmiaday 4
risk of no recovery 22.2% lower · RR 0.78 · p = 0.36 22.2% lowerRR 0.78p = 0.36 21 of 63 (33.3%) 27 of 63 (42.9%) treatment 21 of 63 (33.3%), control 27 of 63 (42.9%)NNT 10myalgiaday 4
risk of no recovery 48.0% lower · RR 0.52 · p = 0.03* 48.0% lowerRR 0.52p = 0.03* 13 of 63 (20.6%) 25 of 63 (39.7%) treatment 13 of 63 (20.6%), control 25 of 63 (39.7%)NNT 5.2loss of tasteday 4
risk of no recovery 46.7% lower · RR 0.53 · p = 0.02* 46.7% lowerRR 0.53p = 0.02* 16 of 63 (25.4%) 30 of 63 (47.6%) treatment 16 of 63 (25.4%), control 30 of 63 (47.6%)NNT 4.5fatigueday 4
risk of no recovery 42.9% lower · RR 0.57 · p = 0.53 42.9% lowerRR 0.57p = 0.53 4 of 63 (6.3%) 7 of 63 (11.1%) treatment 4 of 63 (6.3%), control 7 of 63 (11.1%)NNT 21dizzinessday 4
viral load 61.9% lower · relative load 0.38 · p < 0.001*** 61.9% lowerrelative load 0.38p < 0.001*** 8.38 [7.56-9.2] n=63 3.19 [2.36-4.02] n=63 treatment 8.38 [7.56-9.2] n=63, control 3.19 [2.36-4.02] n=63relative ΔCtday 4

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. * p < 0.05   ** p < 0.01   *** p < 0.001

Mouawia et al., 1 May 2026, Randomized Controlled Trial, Lebanon, peer-reviewed, mean age 40.1, 8 authors, study period November 2021 - December 2021, dosage 12mg single dose, <65kg - 9mg, 65-84kg - 12 mg, ≥85kg - 15 mg, trial ChiCTR2000033627. Contact: raadhoussamrh@gmail.com, houssam.raad@ul.edu.lb, houssein.mouawia@ul.edu.lb.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 Lebanon Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Morocco Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Lebanon favored low-cost treatments.The average efficacy of treatments was moderate.Low-cost treatments improve early treatment, andprovide complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 Lebanon Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Morocco Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Lebanon favored low-cost treatments.The average efficacy was moderate.Low-cost protocols improve early treatment,and add complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Abstract: (2026) 27:447 Mouawia et al. Trials https://doi.org/10.1186/s13063-026-09736-x Trials Open Access RESEARCH Ivermectin therapy is associated with changes in SARS‑CoV‑2 RNA load in asymptomatic patients: a randomized controlled trial Hussein Mouawia1*, Hamid Bou Saab1†, Hassan Ayoub2,3†, Abbas Mourad4†, Najwa Yaghi3, Ahmad Al Saabi1, Mohamed El‑Seblani1 and Houssam Raad1*    Abstract Background Ivermectin, an antiparasitic agent with reported antiviral properties, has been investigated for repurposing in the treatment of COVID-19. This study aimed to assess the efficacy of a single weight-adjusted oral dose of ivermectin in reducing viral load and improving clinical outcomes in asymptomatic individuals infected with SARS-CoV-2. Methods A randomized controlled trial was conducted with 126 asymptomatic SARS-CoV-2-positive participants. Subjects were assigned to receive either standard care (zinc and vitamin C supplementation) or standard care plus a single dose of ivermectin. Reverse transcription-PCR was used to assess changes in cycle threshold (Ct) values after 96 h. Clinical symptom development and hospitalization rates were also monitored. Results Baseline Ct values were similar between groups. After 96 h, participants in the ivermectin group showed a greater increase in Ct values (from 15.97 ± 2.823 to 24.35 ± 3.086) compared with controls (from 16.65 ± 3.593 to 19.84 ± 3.743; p < 0.001), the mean increase in Ct was 8.38 (95% CI, 7.56–9.20) in the ivermectin group versus 3.19 (95% CI, 2.36–4.02) in the control group (mean difference 5.19 (95% CI, 3.72 to 6.66); p < 0.001), suggesting a potential for more rapid reduction in viral load. Participants receiving ivermectin also reported fewer symptoms (e.g., anosmia, fatigue, myalgia) and had a lower hospitalization rate, though these clinical trends should be interpreted cautiously. Conclusion A single oral dose of ivermectin may accelerate viral clearance and reduce symptom progression in asymptomatic SARS-CoV-2-positive individuals. Further large-scale, multi-center randomized trials are warranted to confirm these findings and evaluate ivermectin’s potential role in early COVID-19 management. Trial registration This randomized controlled trial was conducted between November and December 2021 and was registered in the World Health Organization Clinical Trial Registry (ChiCTR2000033627; Date of Registration: 2020-06-07). Keywords Ivermectin, COVID-19, SARS-CoV-2, PCR, Repurposed therapy † Hamid Bou Saab, Hassan Ayoub and Abbas Mourad contributed equally to this work. *Correspondence: Hussein Mouawia houssein.mouawia@ul.edu.lb Houssam Raad raadhoussamrh@gmail.com; houssam.raad@ul.edu.lb Full list of author information is available at the end of the article © The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not..